On July 9, 2025, Mereo BioPharma Group announced that the Phase 3 Orbit study for UX143 in young patients with osteogenesis imperfecta is proceeding as planned, showing an acceptable safety profile. Final analysis is expected by year-end, following an 18-month patient therapy period.